QCG
SMMT icon

Quadrant Capital Group’s Summit Therapeutics SMMT Stock Holding History

Quadrant Capital Group’s Portfolio SMMT Stock Details SMMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-177
Closed -$445 – 2760
2023
Q2 		$445 Buy
+177
New +$323 ﹤0.01% 2579
2021
Q4 		– Sell
-847
Closed -$4K – 2682
2021
Q3 		$4K Buy
847
+467
+123% +$3.35K ﹤0.01% 1964
2021
Q2 		$3K Sell
380
-181
-32% -$1.19K ﹤0.01% 2035
2021
Q1 		$3K Buy
561
+207
+58% +$1.33K ﹤0.01% 1986
2020
Q4 		$2K Buy
+354
New +$1.5K ﹤0.01% 1998

Other funds holding SMMT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
AA
ALPS Advisors Denver, Colorado $21.3B AUM 21.71% 1-Year Est. Return

Quadrant Capital Group's SMMT Position: Q3 2023 in Review

Quadrant Capital Group sold out of Summit Therapeutics (SMMT) in Q3 2023, closing a stake of 177 shares — an estimated $445 sold.

Quadrant Capital Group first reported a position in SMMT in Q4 2020 and held it in 5 quarters. The position peaked at $4K in Q3 2021. 93 funds tracked by Wall St. Rank hold SMMT as of Q3 2023.

  • Quadrant Capital Group reported no remaining Summit Therapeutics position as of Q3 2023 after selling out during the quarter.
  • Quadrant Capital Group sold 177 Summit Therapeutics shares in Q3 2023, an estimated $445.
  • Quadrant Capital Group first reported a position in Summit Therapeutics in Q4 2020 and held it in 5 quarters.
  • Quadrant Capital Group's Summit Therapeutics position peaked at $4K in Q3 2021.
  • 93 funds tracked by Wall St. Rank held Summit Therapeutics as of Q3 2023.

Based on Quadrant Capital Group's 13F filing for Q3 2023, filed 14 Nov 2023.